转移性黑色素瘤再次挑战BRAF靶向治疗的多中心回顾性研究
结果显示再挑战的客观缓解率为43.3%,中位无进展生存期5个月,中位总生存期9.8个月;
要点
- 再挑战BRAF±MEK治疗的缓解率为43.3%,中位PFS 5个月,中位OS 9.8个月。
- 既往因疾病进展停用BRAF抑制剂的患者中,37.3%对再挑战治疗有响应。
核心结论
- 再挑战BRAF±MEK治疗可为部分转移性黑色素瘤患者带来具有临床意义的获益,应考虑用于特定患者。
主要发现
- 再挑战BRAF±MEK的缓解率为43.3%(完全缓解2.6%,部分缓解40.7%,疾病稳定24.8%,疾病进展31.9%,缺失3例)。
- 83例既往因疾病进展停用BRAF抑制剂的患者中,31例(37.3%)对再挑战治疗有响应(30例部分缓解,1例完全缓解)。
- 再挑战治疗的中位总生存期为9.8个月,中位无进展生存期为5个月。
关键数值与推荐
- 再挑战BRAF±MEK的缓解率为43.3%,中位OS 9.8个月,中位PFS 5个月。
临床怎么用
- 对于经过选择的转移性黑色素瘤患者,可考虑在中断BRAF靶向治疗后再次挑战BRAF±MEK治疗,尤其是联合方案可能带来更优生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most metastatic melanoma patients treated with BRAF inhibitors (BRAFi) ± MEK inhibitors (MEKi) eventually progress on treatment. Along with acquired resistance due to genetic changes, epigenetic mechanisms that could be reversed after BRAFi discontinuation have been described. The purpose of this study was to analyse retrospectively outcomes for patients retreated with BRAF-directed therapy. PATIENTS AND METHODS: One hundred sixteen metastatic melanoma patients who received BRAFi-based therapy and, after a break, were rechallenged with BRAFi ± MEKi at 14 centres in Europe, US and Australia were studied, respectively. Response rate (RR), overall survival (OS) and progression-free survival (PFS) from the start of retreatment were calculated. RESULTS: The median duration of treatment was 9.4 months for first BRAFi ± MEKi treatment and 7.7 months for the subsequent treatment (immunotherapy 72%, other 17%, drug holiday 11%) after BRAFi discontinuation. Brain metastases were present in 51 (44%) patients at BRAFi retreatment. The RR to rechallenge with BRAFi ± MEKi was 43.3%: complete response (CR) 2.6%, partial response (PR) 40.7%, stable disease (SD) 24.8% and progressive disease 31.9%, 3 missing. Of 83 patients who previously discontinued BRAFi due to disease progression, 31 (37.3%) responded (30 PR and 1 CR) to retreatment. The median OS from retreatment was 9.8 months, and PFS was 5 months. Independent prognostic factors for survival at rechallenge included number of metastatic sites (hazard ratio [HR] = 1.32 for each additional organ with metastases, P < .001), lactic dehydrogenase (HR = 1.37 for each multiple of the upper normal limit, P < .001), while rechallenge with combination BRAFi + MEKi conferred a better OS versus BRAFi alone (HR = 0.5, P = .006). CONCLUSION: Rechallenge with BRAFi ± MEKi results in a clinically meaningful benefit and should be considered for selected patients.
引用
- Valpione S, Carlino MS, Mangana J, et al. Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. Eur J Cancer. 2018. PMID: 29360604. doi:10.1016/j.ejca.2017.12.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。